PDCD1 and diffuse large B-cell lymphoma: Durvalumab is a mAb that blocks the interaction between PD-L1 and PD-1 and has been studied in combination with ibrutinib in patients with r/r follicular lymphoma or diffuse large B-cell lymphoma (DLBCL).